Assessment of conflicts of interest in literature on monoclonal antibodies for chronic rhinosinusitis with nasal polyposis using the Open Payments Database.
CMS open payments
ChatGPT
biologics
chronic rhinosinusitis
conflict of interest
large language models
nasal polyps
pharmaceutical funding
Journal
International forum of allergy & rhinology
ISSN: 2042-6984
Titre abrégé: Int Forum Allergy Rhinol
Pays: United States
ID NLM: 101550261
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
revised:
05
08
2024
received:
29
03
2024
accepted:
20
08
2024
medline:
2
9
2024
pubmed:
2
9
2024
entrez:
2
9
2024
Statut:
aheadofprint
Résumé
Accurate conflict of interest (COI) information is essential for promoting transparency and trust in research. We aim to assess COI disclosure patterns in monoclonal antibodies (MABs) research for chronic rhinosinusitis with nasal polyposis (CRSwNP) using the Open Payments Database (OPD). Studies on FDA-approved MABs for CRSwNP (dupilumab, omalizumab, mepolizumab) published between 2019 and 2021 with at least one US author were identified through PubMed. Industry-reported payments from the manufacturers (Sanofi, Regeneron, Genentech, Novartis, and GlaxoSmithKline) between 2018 and 2021 in OPD's General Payments category were collected. Authors were cross-checked against OPD metadata using a previously published ChatGPT-based algorithm. Additionally, this novel algorithm analyzed COI statements for relevant author‒company specific disclosures, identifying disclosed and undisclosed payments made 3‒15 months prior to publication. A total of 214 unique authors from 76 studies were included. Of 30 articles that received at least one relevant payment, 21 (70%) were found to have an undisclosed COI, with a mean total undisclosed payment of $4890 and a median of $10,331. Fifty-six authors had relevant OPD payments and 40 (71.4%) authors did not declare a potential COI. Interestingly, 158 authors had no relevant payments and 62 (39.2%) declared a potential COI. Author order was not significantly associated with potential under- or over-disclosure. This study characterizes COI disclosure patterns in rhinosinusitis-relevant MABs research using a novel automated approach. Given the discrepancy between disclosures and industry-reported payments, our findings suggest a need for improved disclosure education and practices.
Sections du résumé
BACKGROUND
BACKGROUND
Accurate conflict of interest (COI) information is essential for promoting transparency and trust in research. We aim to assess COI disclosure patterns in monoclonal antibodies (MABs) research for chronic rhinosinusitis with nasal polyposis (CRSwNP) using the Open Payments Database (OPD).
METHODS
METHODS
Studies on FDA-approved MABs for CRSwNP (dupilumab, omalizumab, mepolizumab) published between 2019 and 2021 with at least one US author were identified through PubMed. Industry-reported payments from the manufacturers (Sanofi, Regeneron, Genentech, Novartis, and GlaxoSmithKline) between 2018 and 2021 in OPD's General Payments category were collected. Authors were cross-checked against OPD metadata using a previously published ChatGPT-based algorithm. Additionally, this novel algorithm analyzed COI statements for relevant author‒company specific disclosures, identifying disclosed and undisclosed payments made 3‒15 months prior to publication.
RESULTS
RESULTS
A total of 214 unique authors from 76 studies were included. Of 30 articles that received at least one relevant payment, 21 (70%) were found to have an undisclosed COI, with a mean total undisclosed payment of $4890 and a median of $10,331. Fifty-six authors had relevant OPD payments and 40 (71.4%) authors did not declare a potential COI. Interestingly, 158 authors had no relevant payments and 62 (39.2%) declared a potential COI. Author order was not significantly associated with potential under- or over-disclosure.
CONCLUSION
CONCLUSIONS
This study characterizes COI disclosure patterns in rhinosinusitis-relevant MABs research using a novel automated approach. Given the discrepancy between disclosures and industry-reported payments, our findings suggest a need for improved disclosure education and practices.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 ARS‐AAOA, LLC.
Références
Rosenbaum L. Understanding bias—the case for careful study. N Engl J Med. 2015;372(20):1959‐1963. doi:10.1056/NEJMms1502497
Bauchner H, Fontanarosa PB, Flanagin A. Conflicts of interests, authors, and journals: new challenges for a persistent problem. JAMA. 2018;320(22):2315‐2318. doi:10.1001/jama.2018.17593
Wayant C, Turner E, Meyer C, Sinnett P, Vassar M. Financial conflicts of interest among oncologist authors of reports of clinical drug trials. JAMA Oncol. 2018;4(10):1426‐1428. doi:10.1001/jamaoncol.2018.3738
Morse E, Fujiwara RJT, Mehra S. Increasing industry involvement in otolaryngology: insights from 3 years of the open payments database. Otolaryngol Neck Surg. 2018;159(3):501‐507. doi:10.1177/0194599818778502
Horn J, Checketts JX, Jawhar O, Vassar M. Evaluation of industry relationships among authors of otolaryngology clinical practice guidelines. JAMA Otolaryngol Neck Surg. 2018;144(3):194‐201. doi:10.1001/jamaoto.2017.2741
Chimonas S, Patterson L, Raveis VH, Rothman DJ. Managing conflicts of interest in clinical care: a national survey of policies at U.S. medical schools. Acad Med J Assoc Am Med Coll. 2011;86(3):293‐299. doi:10.1097/ACM.0b013e3182087156
Weißkircher J, Koch C, Dreimüller N, Lieb K. Conflicts of interest in medicine. A systematic review of published and scientifically evaluated curricula. GMS J Med Educ. 2017;34(3):Doc37. doi:10.3205/zma001114
FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis. Regeneron Pharmaceuticals Inc. Accessed March 26, 2024. https://investor.regeneron.com/news‐releases/news‐release‐details/fda‐approves‐dupixentr‐dupilumab‐chronic‐rhinosinusitis‐nasal/
Safranek C, Liu C, Richmond R, Boyi T, Rimmer R, Manes RP. ChatGPT for automated cross‐checking of authors’ conflicts of interest against industry payments. Otolaryngol–Head Neck Surg. 2024;170:1512‒1518. doi:10.1002/ohn.720
Open Payments Natures of Payment. CMS. Accessed August 4, 2024. https://www.cms.gov/priorities/key‐initiatives/open‐payments/natures
Fabbri A, Hone KR, Hróbjartsson A, Lundh A. Conflict of interest policies at medical schools and teaching hospitals: a systematic review of cross‐sectional studies. Int J Health Policy Manag. 2022;11(8):1274‐1285. doi:10.34172/ijhpm.2021.12
Sharma M, Vadhariya A, Johnson ML, Marcum ZA, Holmes HM. Association between industry payments and prescribing costly medications: an observational study using open payments and Medicare part D data. BMC Health Serv Res. 2018;18:236. doi:10.1186/s12913‐018‐3043‐8
Morse E, Hanna J, Mehra S. The association between industry payments and brand‐name prescriptions in otolaryngologists. Otolaryngol Neck Surg. 2019;161(4):605‐612. doi:10.1177/0194599819852321
Morse E, Fujiwara RJT, Mehra S. Industry payments to physicians and prescriptions of brand‐name proton‐pump inhibitors. Otolaryngol Neck Surg. 2019;160(1):70‐76. doi:10.1177/0194599818803337
Morse E, Fujiwara RJT, Mehra S. The association of industry payments to physicians with prescription of brand‐name intranasal corticosteroids. Otolaryngol Neck Surg. 2018;159(3):442‐448. doi:10.1177/0194599818774739
Rosenbaum L. Beyond moral outrage—weighing the trade‐offs of COI regulation. N Engl J Med. 2015;372(21):2064‐2068. doi:10.1056/NEJMms1502498
Rosenbaum L. Reconnecting the dots—reinterpreting industry–physician relations. N Engl J Med. 2015;372(19):1860‐1864. doi:10.1056/NEJMms1502493
Drazen JM. Revisiting the commercial–academic interface. N Engl J Med. 2015;372(19):1853‐1854. doi:10.1056/NEJMe1503623
Physicians Still Foggy on Accuracy of Sunshine Act Data. December 2021. Accessed March 28, 2024. https://ashpublications.org/ashclinicalnews/news/1985/Physicians‐Still‐Foggy‐on‐Accuracy‐of‐Sunshine‐Act
CMS Releases Open Payments Data; Concerns Raised Over Accuracy and Context. Endovascular Today. Accessed March 28, 2024. https://evtoday.com/news/cms‐releases‐first‐round‐of‐open‐payments‐data
Review and Dispute for Open Payments Covered Recipients. CMS. Accessed March 28, 2024. https://www.cms.gov/openpayments/program‐participants/covered‐recipients/review‐and‐dispute